PE Guidelines logo
Pharmacoeconomic Guidelines Around The World

Country/Region: Taiwan

PE Guidelines

PDF in Chinese

PDF in English

HTA guidelines in Taiwan (Chinese)

PE Guidelines Source:
Taiwan Society for Pharmacoeconomics and Outcomes Research
http://www.taspor.org.tw/

Additional Information:

Last Webpage Update: Tuesday, January 23, 2018

PE Guidelines Key Features:

Key Features:  
Title and year of the documentGuidelines of Methodological Standards for Pharmacoeconomic Evaluations (2006) 
Affiliation of authorsTaiwan Society for Pharmacoeconomic and Outcomes Research (TaSPOR) 
Purpose of the documentProvide stakeholders a guide to conduct, evaluate and report a PE study 
Standard reporting format includedYes 
DisclosureYes 
Target audience of funding/ author's interestsShould state clearly 
PerspectiveMainly societal, may separate into payer and others 
IndicationShould be approved by the regulatory body 
Target populationState clearly, may include subgroup analysis 
Subgroup analysisYes. Treatment regimen, disease groups, symptom complex, severity of disease, patient characteristics 
Choice of comparatorThe one most likely to be replaced, first choice, most effective one, most frequently used. 
Time horizonLong enough to cover all significant clinical and cost consequences that are directly related to the intervention. 
Assumptions requiredYes 
Preferred analytical techniqueThe most appropriate method that can reflect the purpose of the study 
Costs to be includedDepends on the perspective of the study. Recommend human capital approach for estimation of indirect cost 
Source of costsDirect costs from BNHI reimbursement price, state clearly the sources, reflect Taiwan situations 
ModelingYes, requires details 
Systematic review of evidencesRecommended 
Preference for effectiveness over efficacyYes. Recommend meta-analysis of effectiveness. 
Preferred outcome measureLife-year gained and QALY 
Preferred method to derive utilityAll can be accepted, using general publicís views 
Equity issues statedYes 
Discounting costsBase: 3%; SA: 0 ~ 5% 
Discounting outcomesThree scenarios: discount cost but not outcome, both discounted, both not discounted 
Sensitivity analysis-parameters and rangeAll assumptions should be subject to SA. 
Sensitivity analysis-methodsUnivariate, Multivariate (best and worst case estimate), 
Presenting resultsBoth in aggregated and disaggregated form 
Incremental analysisYes 
Total costs vs effectiveness (cost/effectiveness ratio)Yes 
Portability of results (Generalizability)Yes, Taiwan context, especially the cost issue and epidemiology data 
Financial impact analysisYes 
Mandatory or recommended or voluntaryVoluntary 

Acknowledgement: Tony Yen-Huei Tarn contributed to the key feature form.

Country Selection Page | PE Guidelines Index Page